Navigation Links
ApoA-I Data Presented at European Society of Cardiology Congress
Date:9/2/2008

Multiple presentations included Resverlogix data

TSX Exchange Symbol: RVX

CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Dr. Norman Wong presented key clinical data pertaining to its lead compound, RVX-208, at the European Society Cardiology (ESC) 2008 Congress in Munich. The presentation titled "RVX-208 a novel small molecule that increases apolipoprotein A-I enters into human clinical trials" was delivered on August 31, 2008. In addition to this presentation, other important data relating to RVX-208 from Resverlogix's extensive data portfolio was presented by Dr. Jacques Genest of McGill University and Dr. Stephen Nicholls of the Cleveland Clinic, at the same conference.

"Over the past year, the scientific community has pushed to the forefront the importance of a small molecule in the form of an oral tablet that significantly increases ApoA-I production, HDL functionality and thereby treats atherosclerosis cardiovascular disease," stated Dr. Jan Johansson, Senior Vice President Medical Affairs Resverlogix. Johansson further added, "The ESC is a well regarded scientific meeting as well as one of the largest with an estimated 25,000 participants. We are pleased to have presented our data to this esteemed audience."

Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for elimination from the body. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans.

RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I production, is positioned as an emerging drug that holds the most promise for the trea
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
2. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
3. Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association
4. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
5. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
6. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
7. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
8. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
9. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
10. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... PuraMed BioScience ® , Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced that Ludlow ... based on low market capitalization valuation. ... Product to Treat Migraine Headaches , Clinical ... , Currently Available Nationwide at Walgreen,s and ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... , May 23, 2013 Pusan ... Inc., a private biotherapeutics and contract research company ... products for cancer, announced today a publication reporting ... treated with the oncolytic and immunotherapeutic vaccinia JX-594 ... research was published in the May 15 th ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3
... Inc. (TSX: ONC, NASDAQ: ONCY ) ("Oncolytics") ... U.S. Patent, # 7,582,289, entitled "Viruses for the Treatment ... of using modified parapoxvirus orf virus to treat Ras-mediated ... portfolio regarding oncolytic viruses, in addition to reovirus, that ...
... WILMINGTON, Delaware, September 1 According ... (2009-2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ), the,global autoimmune ... 2014, with an estimated CAGR of 12.7% from 2009 ... for nearly 42% of the total revenues. , ...
... ... of continuous research, experiments and trials have given Centre for Jatropha Promotion ... alternative feedstock for biodiesel. After having a number of successful field trials ... source for Bio- Diesel industry of future and is happy to announce ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4Derris Indica is CJP's New Nonfood Biodiesel Crop for Profitable Sustainability 2Derris Indica is CJP's New Nonfood Biodiesel Crop for Profitable Sustainability 3
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
(Date:5/23/2013)... discovering the new mechanism by which estrogen suppresses lipid ... a potential new approach toward treating certain liver diseases. ... colleagues believe they are changing long-held views in the ... of the journal Science Signaling . , "The ... has been that only receptors located in the nucleus ...
(Date:5/23/2013)... 23, 2013) A new report from the Institute ... pupils engage in at least 60 minutes of vigorous ... No more than half of American youth meet current ... or moderate intensity physical activity daily, according to the ... are in school for nearly half of their waking ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide students with daily physical activity, IOM recommends 2
... of obesity among South Asians to be recalculated has been ... A team from the University,s Departments of Health Sciences and ... which South Asians should be classed as obese to be ... One , a journal of the Public Library of Science. ...
... three-person start-up may well be on its way to ... team of young Dutch scientists pushing disruptive biotech innovations ... attention of some key investors and demonstrating the added ... with the Eurostars funding programme leading the way. ...
... Spanish . CHICAGO -- A 10-year ... infants with high hemoglobin levels who received iron fortified infant ... in Santiago, Chile, was published online today ahead of print ... and raises questions about the optimal amount of iron in ...
Cached Biology News:New research calls for lower limit to be set for South Asian obesity level 2Biotech start-up brings DNA-sequencing to the medical market 2Biotech start-up brings DNA-sequencing to the medical market 3Routine iron fortification of infant formula linked to poorer development 2Routine iron fortification of infant formula linked to poorer development 3
Mouse monoclonal antibody raised against a partial recombinant CALCOCO2. NCBI Entrez Gene ID = CALCOCO2...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This ...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: